Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Canadian Tire Corporation, Limited (CDNTF) Income Statement Analysis – Financial Results
- Nissin Electric Co., Ltd. (6641.T) Income Statement Analysis – Financial Results
- Natori Co., Ltd. (2922.T) Income Statement Analysis – Financial Results
- 3onedata Co., Ltd. (688618.SS) Income Statement Analysis – Financial Results
- Skydeck Acquisition Corp. (SKYA) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
Corgenix Reports Fiscal 2011 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal year Form 10-K and reported financial results. The report disclosed that the company’s operating results have advanced for the fiscal...
Corgenix to Host Conference Call to Discuss Fiscal 2011 Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Friday, September 23, 2011, at 4:00 p.m. EDT to discuss the Company’s financial and operating performance for its...
Corgenix Provides Preliminary Sales Guidance on FY 2011 Financials
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today reported that preliminary sales results were much stronger in the fourth quarter (ended June 30, 2011) than the initial three fiscal quarters, coming...
Corgenix Announces Extension of ELITech Joint Product Development Agreement and Expansion of Manufacturing Capabilities
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX OB), a worldwide developer and marketer of diagnostic test kits, today announced a three-year extension of the Joint Product Development Agreement with the ELITech Group, a Paris, France-based, privately held group of companies...
CORRECTING and REPLACING Corgenix Teams up with Strategic Partners at AACC Clinical Lab Expo 2011
DENVER--(BUSINESS WIRE)--Please replace the release with the following corrected version due to the incorrect version being issued. Headline of release should read: Corgenix Teams up with Strategic Partners at AACC Clinical Lab Expo 2011 (sted Corgenix Medical Corporation Announces New...
Corgenix Medical Corporation Announces New Three-Year, $1.5 Million Revolving Credit Facility
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB:CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with LSQ Funding Group, L.C. (LSQ). The new revolving line of...
Corgenix Reports Third Quarter Fiscal 2011 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB:CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-Q and reported its financial results. Some of the results highlighted by the report are as follows: Revenues were...
New Aspirin Test Now Available Through Diagnostic Laboratory Medicine
BEDFORD, Mass.--(BUSINESS WIRE)--A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks® Test (www.aspirinworks.com) is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine (www.dlmlabs.com)....
Corgenix to Host Conference Call to Discuss Third Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Friday, May 13, 2011, at 4:00 p.m. EDT (2:00 p.m. MDT) to discuss the Company’s financial and operating...
Corgenix Medical Reaches Milestone in Development of New Test Format
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX.PK) has successfully completed the feasibility stage for a new, high-speed automated test format for its AspirinWorks® Test. Developed in collaboration with Randox Laboratories, the new format will make it faster and easier to perform...
Source: https://incomestatements.info
Category: Stock Reports